Insulet (Nasdaq:PODD) shares rose slightly before hours today on third-quarter results that landed well ahead of the consensus forecast. Shares of PODD ticked up 2.4% to $322 apiece in pre-market trading today. The Acton, Massachusetts-based automated insulin delivery technology developer reported profits of $87.6 million. That equals $1.24 per share on sales of $706.3 million […]
MassDevice Earnings Roundup
Senseonics posts Q3 sales beat, expects CE mark for Eversense 365 this year
Senseonics (NYSE:SENS) shares ticked up after hours today on third-quarter results that beat the consensus sales forecast. Shares of SENS rose 2.1% to $6.87 apiece in post-market trading today. The Germantown, Maryland-based long-term implantable continuous glucose monitor (CGM) maker reported losses of $19.5 million. That equals 43¢ per share on sales of $8.1 million for […]
Dexcom leadership addresses G7 issue claims, hopes for expanded CGM coverage
Amid some scrutiny over its latest-generation G7 continuous glucose monitor (CGM), Dexcom (Nasdaq:DXCM) officials addressed claims on the company’s latest earnings call. A recent class action lawsuit brought G7 into the spotlight, demanding a jury trial for claims that Dexcom’s representations for G7 were false, misleading, and deceptive to consumers. The lawsuit says G7 places […]
Dexcom stock is down after hours despite Q3 beats, raised sales guidance
Dexcom (Nasdaq:DXCM) shares took a hit after hours today on third-quarter results that came in ahead of the consensus forecast. Shares of DXCM fell more than 8% to $62.69 apiece after the market closed today. The San Diego-based continuous glucose monitor (CGM) maker reported profits of $283.8 million. That equals 70¢ per share on sales […]
Beta Bionics stock rises on Q3 beats, raised full-year guidance, advances iLet offerings
Beta Bionics (Nasdaq:BBNX) shares got a boost after hours today on third-quarter results that came in ahead of the consensus forecast. Shares of BBNX rose around 20% to $29 apiece in post-market trading today. The Irvine, California-based automated insulin delivery device maker reported losses of $14 million. That equals 33¢ per share on sales of […]
Abbott CEO expects continued growth in Diabetes Care with Libre 3, dual sensor
Abbott (NYSE:ABT) continues to get a boost in its Medical Devices business from its Diabetes Care unit’s portfolio of continuous glucose monitors (CGMs). In the company’s third-quarter earnings report released today, Abbott — one of the largest medtech companies in the world — fell shy of Wall Street’s sales expectations, but still reported more than 15% […]
Senseonics posts strong preliminary Q3 sales, reverse stock split
Senseonics (NYSE:SENS) today announced preliminary revenues for the third quarter and plans to conduct a reverse stock split. The Germantown, Maryland-based long-term implantable continuous glucose monitor maker expects approximately $8.1 million in revenue for the third quarter of 2025. That marks a 91% uptick from the third quarter of 2024. The company attributed its growth […]
Court dismisses several claims against Dexcom in securities lawsuit
A California judge has dismissed several claims against Dexcom (Nasdaq:DXCM) officials related to alleged misrepresentation of sales efforts. Judge Robert S. Huie of the Southern District of California ruled in the consolidated action, which combines three securities class actions against the San Diego-based continuous glucose monitor (CGM) maker. Huie’s judgment denied Dexcom’s motion to dismiss […]
Medtronic says MiniMed separation remains on track, next-gen pump submissions on the way
Medtronic (NYSE:MDT) officials today said that the company’s planned separation of its Diabetes business is on the right track. The medtech giant announced in May that it planned to separate the Diabetes unit into a standalone, publicly traded company. The move sought to create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. […]
Embecta stock gets a boost on Q3 beats, raised guidance
Embecta (Nasdaq:EMBC) shares ticked up today on third-quarter results that came in ahead of the consensus forecast on Wall Street. Shares of EMBC 17% to $12.12 apiece in early-morning trading today. The Parsippany, New Jersey-based diabetes technology company — which spun off from BD three years ago — reported profits of $45.5 million. That equals […]
